Regnum Corp. (RGMP)
Regnum Corp. operates in the Biotechnology industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $2,295. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of -0.81 implies it has historically moved less than the broad market.
Regnum Corp. is dedicated to advancing and marketing therapeutic agents designed to combat both rare and infectious diseases. Its flagship product is Leronlimab (PRO 140), a monoclonal antibody functioning as a C-C chemokine receptor type 5 (CCR5) antagonist. This drug is specifically formulated to inhibit the human immunodeficiency virus (HIV) from gaining entry into human cells. Headquartered in New York, New York, Regnum Corp. operates as a subsidiary of Phoenixus AG.
Regnum Corp. is most often compared with the following Healthcare names: